Save your place

Sign in to WhoBought

Please try again later.

Xenon Pharmaceuticals Inc. (XENE) institutional ownership

Latest close $65.78 Jul 27, 2026
Market cap$2.3B 52-week range SectorHealthcare
Funds holding · Q1 2026
287
reported XENE position changes
Top owners · Q1 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
192 buyers · 95 sellers

Xenon Pharmaceuticals Inc. (XENE) price and institutional activity

Dates

Q1 2026

$0 bought by 192 investors
Polar Capital Holdings PLCFMR LLC +190 more
$0 sold by 95 investors
Commodore Capital LPCapital International Investors +93 more
Bought Sold Totals per quarter; hover a bar for the names.

Xenon Pharmaceuticals Inc. (XENE) institutional activity · 287

Investor Type Est. change Change Δ Own Date
Polar Capital Holdings PLC · Added
Change +1.9M Date Q1 2026
Polar Capital Holdings PLC Added· Q1 2026 +1.9M Q1 2026
FMR LLC · Added
Change +1.9M Δ Own +21.3% Date Q1 2026
FMR LLC Added· Q1 2026 +1.9M +21.3% Q1 2026
Citadel Advisors LLC Added· Q1 2026 +1.3M +100.8% Q1 2026
Alyeska Investment Group, L.P. · New
Change +1.3M Date Q1 2026
Alyeska Investment Group, L.P. New· Q1 2026 +1.3M Q1 2026
Deerfield Management Company, L.P. · Added
Change +1.1M Date Q1 2026
Deerfield Management Company, L.P. Added· Q1 2026 +1.1M Q1 2026
Commodore Capital LP · Reduced
Change −975K Date Q1 2026
Commodore Capital LP Reduced· Q1 2026 −975K Q1 2026
Caligan Partners LP · Added
Change +843K Date Q1 2026
Caligan Partners LP Added· Q1 2026 +843K Q1 2026
Capital International Investors · Reduced
Change −740K Date Q1 2026
Capital International Investors Reduced· Q1 2026 −740K Q1 2026
Orbimed Advisors LLC · Added
Change +613K Date Q1 2026
Orbimed Advisors LLC Added· Q1 2026 +613K Q1 2026
BlackRock · Added
Change +540K Date Q1 2026
BlackRock Added· Q1 2026 +540K Q1 2026
Siren, L.L.C. · Added
Change +506K Date Q1 2026
Siren, L.L.C. Added· Q1 2026 +506K Q1 2026
Octagon Capital Advisors LP · New
Change +490K Date Q1 2026
Octagon Capital Advisors LP New· Q1 2026 +490K Q1 2026
Braidwell LP · Reduced
Change −487K Date Q1 2026
Braidwell LP Reduced· Q1 2026 −487K Q1 2026
Novo Holdings A · New
Change +485K Date Q1 2026
Novo Holdings A New· Q1 2026 +485K Q1 2026
T. Rowe Price Associates · Added
Change +467K Date Q1 2026
T. Rowe Price Associates Added· Q1 2026 +467K Q1 2026
Data through Q1 2026 · filed Jun 9, 2026
15 of 287

Famous investor activity in Xenon Pharmaceuticals Inc. (XENE)

Xenon Pharmaceuticals Inc. (XENE) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Patou Gary · Director Sell −$70K
Price $53.14 Qty −1K Owned 25K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Patou Gary Director Sell $53.14 −1K −$70K 25K Jun 5, 2026 Jun 8, 2026
Cannon Gillian · Director Sell −$63K
Price $53.14 Qty −1K Owned 1K Trade date Jun 5, 2026 Filed date Jun 8, 2026
Cannon Gillian Director Sell $53.14 −1K −$63K 1K Jun 5, 2026 Jun 8, 2026
Patou Gary · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Patou Gary Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Machado Patrick · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Machado Patrick Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Gover Justin D. · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Gover Justin D. Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Garofalo Elizabeth A. · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Garofalo Elizabeth A. Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Gannon Steven · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Gannon Steven Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Cannon Gillian · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Cannon Gillian Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Svoronos Dawn · Director 2 operations 12K
Owned 2K Trade date Jun 3, 2026 Filed date Jun 3, 2026
Svoronos Dawn Director 2 operations 12K 2K Jun 3, 2026 Jun 3, 2026
Patou Gary · Director 2 operations 0
Owned 0 Trade date Jun 1, 2026 Filed date Jun 3, 2026
Patou Gary Director 2 operations 0 0 Jun 1, 2026 Jun 3, 2026
Machado Patrick · Director 2 operations 0
Owned 0 Trade date Jun 1, 2026 Filed date Jun 3, 2026
Machado Patrick Director 2 operations 0 0 Jun 1, 2026 Jun 3, 2026
Gover Justin D. · Director 2 operations 0
Owned 0 Trade date Jun 1, 2026 Filed date Jun 3, 2026
Gover Justin D. Director 2 operations 0 0 Jun 1, 2026 Jun 3, 2026
Garofalo Elizabeth A. · Director 2 operations 0
Owned 0 Trade date Jun 1, 2026 Filed date Jun 3, 2026
Garofalo Elizabeth A. Director 2 operations 0 0 Jun 1, 2026 Jun 3, 2026
Gannon Steven · Director 2 operations 0
Owned 0 Trade date Jun 1, 2026 Filed date Jun 3, 2026
Gannon Steven Director 2 operations 0 0 Jun 1, 2026 Jun 3, 2026
Gannon Steven · Director Tax withholding or exercise payment (F) -$76K
Price $53.41 Qty -1K Owned 12K Trade date Jun 1, 2026 Filed date Jun 3, 2026
Gannon Steven Director Tax withholding or exercise payment (F) $53.41 -1K -$76K 12K Jun 1, 2026 Jun 3, 2026
15 of 47
15 of 47 Sign in to continue to older insider transactions.

Xenon Pharmaceuticals Inc. (XENE) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
FMR LLC 6.9M
% of shares outstanding 9.1% Filing date Nov 12, 2024
FMR LLC 6.9M 9.1% Nov 12, 2024
Avoro Capital Advisors LLC 5.8M
% of shares outstanding 6.3% Filing date May 15, 2026
Avoro Capital Advisors LLC 5.8M 6.3% May 15, 2026
Wellington Management Group LLP 4.2M
% of shares outstanding 5.6% Filing date Feb 8, 2024
Wellington Management Group LLP 4.2M 5.6% Feb 8, 2024
Driehaus Capital Management LLC 4.5M
% of shares outstanding 4.9% Filing date May 15, 2026
Driehaus Capital Management LLC 4.5M 4.9% May 15, 2026
Janus Henderson Group PLC 4.2M
% of shares outstanding 4.5% Filing date May 15, 2026
Janus Henderson Group PLC 4.2M 4.5% May 15, 2026
Point72 Asset Management, L.P. 1.2M
% of shares outstanding 1.9% Filing date Feb 14, 2023
Point72 Asset Management, L.P. 1.2M 1.9% Feb 14, 2023
Adage Capital Partners Gp, L.L.C. 665K
% of shares outstanding 1.3% Filing date Feb 10, 2022
Adage Capital Partners Gp, L.L.C. 665K 1.3% Feb 10, 2022
Orbimed Advisors LLC 631K
% of shares outstanding 1.2% Filing date Feb 11, 2022
Orbimed Advisors LLC 631K 1.2% Feb 11, 2022
8 of 9

Xenon Pharmaceuticals Inc. (XENE) ownership FAQ

Who owns XENE?

287 reporting institutions disclosed XENE position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.